← Business Alignment overview

Business Alignment vs Integer: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Business Alignment Public Company Limited (BIZ.BK)

Q3 2026
▲4

BIZ profit jumps, BIZGENES launch and Forbes nod lift growth story

  • Q2 profit surge and double-digit growth target BIZ's second-quarter 2026 net profit jumped 87.75% to 85.18 million baht and revenue rose 29.51%, with management keeping its double-digit full-year growth target. Strong earnings and a 1.259 billion baht backlog give investors confidence in future revenue, pushing the stock up.

    The profit surge and maintained growth target are the core new financial results driving the stock.

  • BIZGENES launch opens new longevity market BIZ launched BIZGENES, a Thai DNA testing and precision health brand, to capture the healthy-longevity trend. It is expanding marketing and service channels across hospitals, clinics and consumers. This new business line adds future revenue and supports the growth story, lifting the stock.

    The BIZGENES brand launch is a new growth driver that expands BIZ's addressable market.

  • Forbes Asia recognition boosts credibility BIZ was named to Forbes Asia's Best Under A Billion list for 2026, one of 18 Thai companies selected. Such recognition raises the company's profile with investors and can attract new buyers, supporting demand for the shares.

    The Forbes award is a new external validation that can improve investor sentiment and visibility.

  • Strong governance score and new project bidding BIZ scored a perfect 100 on the 2026 AGM Checklist for the third straight year, signaling good governance. It is also bidding for government and medical school projects and aims for 200 million baht in recurring after-sales revenue within 2-3 years, supporting future earnings.

    The governance score and bidding activity are new positive factors that reinforce the growth outlook.

August 2026
▲4

BIZ profit jumps, BIZGENES launch and Forbes nod lift growth story

  • Q2 profit surge and double-digit growth target BIZ's second-quarter 2026 net profit jumped 87.75% to 85.18 million baht and revenue rose 29.51%, with management keeping its double-digit full-year growth target. Strong earnings and a 1.259 billion baht backlog give investors confidence in future revenue, pushing the stock up.

    The profit surge and maintained growth target are the core new financial results driving the stock.

  • BIZGENES launch opens new longevity market BIZ launched BIZGENES, a Thai DNA testing and precision health brand, to capture the healthy-longevity trend. It is expanding marketing and service channels across hospitals, clinics and consumers. This new business line adds future revenue and supports the growth story, lifting the stock.

    The BIZGENES brand launch is a new growth driver that expands BIZ's addressable market.

  • Forbes Asia recognition boosts credibility BIZ was named to Forbes Asia's Best Under A Billion list for 2026, one of 18 Thai companies selected. Such recognition raises the company's profile with investors and can attract new buyers, supporting demand for the shares.

    The Forbes award is a new external validation that can improve investor sentiment and visibility.

  • Strong governance score and new project bidding BIZ scored a perfect 100 on the 2026 AGM Checklist for the third straight year, signaling good governance. It is also bidding for government and medical school projects and aims for 200 million baht in recurring after-sales revenue within 2-3 years, supporting future earnings.

    The governance score and bidding activity are new positive factors that reinforce the growth outlook.

Latest
▲4

BIZ profit jumps, BIZGENES launch and Forbes nod lift growth story

  • Q2 profit surge and double-digit growth target BIZ's second-quarter 2026 net profit jumped 87.75% to 85.18 million baht and revenue rose 29.51%, with management keeping its double-digit full-year growth target. Strong earnings and a 1.259 billion baht backlog give investors confidence in future revenue, pushing the stock up.

    The profit surge and maintained growth target are the core new financial results driving the stock.

  • BIZGENES launch opens new longevity market BIZ launched BIZGENES, a Thai DNA testing and precision health brand, to capture the healthy-longevity trend. It is expanding marketing and service channels across hospitals, clinics and consumers. This new business line adds future revenue and supports the growth story, lifting the stock.

    The BIZGENES brand launch is a new growth driver that expands BIZ's addressable market.

  • Forbes Asia recognition boosts credibility BIZ was named to Forbes Asia's Best Under A Billion list for 2026, one of 18 Thai companies selected. Such recognition raises the company's profile with investors and can attract new buyers, supporting demand for the shares.

    The Forbes award is a new external validation that can improve investor sentiment and visibility.

  • Strong governance score and new project bidding BIZ scored a perfect 100 on the 2026 AGM Checklist for the third straight year, signaling good governance. It is also bidding for government and medical school projects and aims for 200 million baht in recurring after-sales revenue within 2-3 years, supporting future earnings.

    The governance score and bidding activity are new positive factors that reinforce the growth outlook.

Integer Holdings Corp (ITGR)

Q3 2026
▲1▼1

KKR's $127/share buyout drives ITGR, with approval risk remaining

  • KKR buyout at $127 per share KKR agreed to buy Integer for $127 per share in cash, a $5.7 billion deal at a 51.8% premium. The stock now trades near the offer, so price reflects the deal, not company performance.

    This is the dominant new event that now defines ITGR's stock price.

  • Deal approval still pending Financing is secured, but the deal still needs shareholder and regulatory approval. Analysts downgraded to neutral, and fair-value estimates of $112–$139 sit around the offer, showing limited upside unless a higher bid emerges.

    It explains the main remaining risks and why the stock trades near the offer.

  • Weak Q2 results and withdrawn guidance Q2 profit fell to $23.6 million from $37 million, revenue slipped 2.6%, and gross margin narrowed to 24.3%. Management withdrew guidance and canceled its earnings call, removing forward-looking data for investors.

    It is the key counterweight showing underlying business weakness behind the deal.

  • Investor-rights review may seek higher bid An investor-rights law firm is reviewing whether $127 is fair and may seek a higher bid. This creates a small chance of a bump, but also adds uncertainty around the deal's final price.

    It highlights a potential upside catalyst and a source of deal uncertainty.

August 2026
▲1▼1

KKR's $127 Cash Buyout Sets ITGR's Price, Despite Weak Q2

  • KKR buyout locks in $127 cash per share Integer agreed to be bought by KKR for $127 per share in cash, a $5.7 billion deal. That price now anchors the stock, because shareholders expect to receive it when the deal closes. The buyer already has financing, so the main remaining hurdles are a shareholder vote and regulatory approvals.

    The buyout is the single force now setting ITGR's price and the main answer to why it moves.

  • Weak Q2 profit and sales, margins squeezed Second-quarter profit fell to $23.61 million from $37.01 million, and revenue slipped 2.6% to $464.1 million. Gross margin shrank to 24.3% from 27.1%. This weak operating picture is a counterweight: it shows the business was softening even as the buyout price caps the stock.

    It is the main negative fundamental fact and the real counterweight to the buyout.

  • Company drops guidance and earnings call Integer withdrew its financial outlook and canceled its quarterly earnings call, saying merger progress now matters more than operating targets. For investors this removes forward-looking numbers, so the stock trades on deal news rather than company performance. It also signals management is focused on closing the KKR sale.

    It explains why ordinary operating news no longer drives the stock and why the deal dominates.

  • Law firm review may seek a higher price An investor-rights law firm is investigating whether the $127-per-share KKR sale is fair and may push for more money or extra disclosures. Such reviews are common in buyouts. If they lead to a raised bid, the stock could rise above $127; if not, they are mostly noise.

    It is the only new event that could change the deal price, so it matters to the buyout story.

Latest
▲1▼1

KKR's $127 Cash Buyout Sets ITGR's Price, Despite Weak Q2

  • KKR buyout locks in $127 cash per share Integer agreed to be bought by KKR for $127 per share in cash, a $5.7 billion deal. That price now anchors the stock, because shareholders expect to receive it when the deal closes. The buyer already has financing, so the main remaining hurdles are a shareholder vote and regulatory approvals.

    The buyout is the single force now setting ITGR's price and the main answer to why it moves.

  • Weak Q2 profit and sales, margins squeezed Second-quarter profit fell to $23.61 million from $37.01 million, and revenue slipped 2.6% to $464.1 million. Gross margin shrank to 24.3% from 27.1%. This weak operating picture is a counterweight: it shows the business was softening even as the buyout price caps the stock.

    It is the main negative fundamental fact and the real counterweight to the buyout.

  • Company drops guidance and earnings call Integer withdrew its financial outlook and canceled its quarterly earnings call, saying merger progress now matters more than operating targets. For investors this removes forward-looking numbers, so the stock trades on deal news rather than company performance. It also signals management is focused on closing the KKR sale.

    It explains why ordinary operating news no longer drives the stock and why the deal dominates.

  • Law firm review may seek a higher price An investor-rights law firm is investigating whether the $127-per-share KKR sale is fair and may push for more money or extra disclosures. Such reviews are common in buyouts. If they lead to a raised bid, the stock could rise above $127; if not, they are mostly noise.

    It is the only new event that could change the deal price, so it matters to the buyout story.

July 2026
▲2▼1

KKR's $127-a-share buyout deal is now the whole story for ITGR

  • KKR agrees to buy Integer for $127 a share KKR signed a definitive deal to take Integer private for $127 a share in cash, about $5.7 billion, a 51.8% premium to the price before the strategic review. The stock jumped toward the offer, and the deal is expected to close by year-end.

    This is the single new event that now sets ITGR's price, so it is the core answer.

  • No financing risk, but a vote and regulators must clear it The buyer needs no financing, so the main risks are stockholders approving the deal and regulators clearing it. If it closes, Integer leaves the New York Stock Exchange and becomes privately held, so the shares stop trading publicly.

    Explains the real conditions and counterweight behind the agreed deal, which readers need to judge it.

  • Analysts cut ratings; fair-value estimates still sit below the offer After the deal, analysts downgraded the stock to neutral, saying further gains depend on the deal closing. One fair-value estimate rose to $112.14, still under the $127 offer, while another model says $139. This shows the price is now pinned near the deal terms, not company performance.

    Gives the honest counterweight: upside is limited and tied to completion, not to the business.

  • Insurance-driven procedure slowdown is now a side issue An Intuitive Surgical warning that insurance changes could slow U.S. procedures briefly dragged medical device stocks down, including Integer. With the buyout agreed, this demand worry matters far less to the price than the deal itself.

    It is the only negative force this period, but the buyout has largely overtaken it.

▲2▼1

KKR's $127-a-share buyout deal is now the whole story for ITGR

  • KKR agrees to buy Integer for $127 a share KKR signed a definitive deal to take Integer private for $127 a share in cash, about $5.7 billion, a 51.8% premium to the price before the strategic review. The stock jumped toward the offer, and the deal is expected to close by year-end.

    This is the single new event that now sets ITGR's price, so it is the core answer.

  • No financing risk, but a vote and regulators must clear it The buyer needs no financing, so the main risks are stockholders approving the deal and regulators clearing it. If it closes, Integer leaves the New York Stock Exchange and becomes privately held, so the shares stop trading publicly.

    Explains the real conditions and counterweight behind the agreed deal, which readers need to judge it.

  • Analysts cut ratings; fair-value estimates still sit below the offer After the deal, analysts downgraded the stock to neutral, saying further gains depend on the deal closing. One fair-value estimate rose to $112.14, still under the $127 offer, while another model says $139. This shows the price is now pinned near the deal terms, not company performance.

    Gives the honest counterweight: upside is limited and tied to completion, not to the business.

  • Insurance-driven procedure slowdown is now a side issue An Intuitive Surgical warning that insurance changes could slow U.S. procedures briefly dragged medical device stocks down, including Integer. With the buyout agreed, this demand worry matters far less to the price than the deal itself.

    It is the only negative force this period, but the buyout has largely overtaken it.